Skip to main content

Advertisement

SpringerLink
Log in

Anti-Interleukin-1 Therapy in the Management of Gout

  • CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Gout is the most common inflammatory arthritis in humans. Current treatment options to control the pain and inflammation of acute and chronic gout include nonsteroidal anti-inflammatory drugs, colchicine, and corticosteroids. However, patients are commonly unresponsive to, intolerant of, or have contraindications to current treatments. Interleukin-1 (IL-1), a proinflammatory cytokine, plays a major role in mediating gouty inflammation. This role of IL-1 has led investigators to explore a new class of anti-inflammatory drugs that inhibit IL-1 signal transduction. IL-1 inhibitors currently in trials for gout include anakinra, rilonacept, and canakinumab. Anakinra is an IL‑1 receptor antagonist that inhibits the activity of both IL‑1α and IL‑1β, rilonacept is a soluble decoy receptor and canakinumab is an anti‑IL‑1β monoclonal antibody. In case cohorts, anakinra was found to be efficacious in combating acute gout pain and inflammation, whereas rilonacept has been found to be efficacious for reducing the risk of recurrent attacks. Canakinumab has been shown to be efficacious in both reducing pain and inflammation in acute attacks, and for reducing the risk of recurrent attacks. All three IL-1 inhibitors are generally well tolerated. This article reviews the current IL-1 inhibitors and the results of trials in which they have been tested for the management of acute and chronic gouty inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41. This is an excellent paper addressing incidence of frequency of gout in the USA.

  2. • Keenan RT, O'Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155–63. This is an excellent paper addressing much needed information about comorbidities in gout and how they affect prescriptions.

  3. Chen CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116:2262–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal- induced IL-1. J Immunol. 1987;138:3213–8.

    PubMed  Google Scholar 

  5. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.

    Article  CAS  PubMed  Google Scholar 

  6. Cronstein RN, Terkeltaub R. The inflammatory process of gout and its treatment. Arthritis Res Ther. 2006;8 Suppl 1:S3.

    Article  PubMed Central  PubMed  Google Scholar 

  7. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Cho M, Ghosh P, Hans G, Rhiannon J, Gardner GC, Simkin PA. The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients. Arthritis Rheum. 2010;60(9, Supplement):S163.

    Google Scholar 

  9. Chen K, Fields T, Mancuso CA, Bass AR, Vasanth L. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum. 2010;40:210–4.

    Article  CAS  PubMed  Google Scholar 

  10. Ottaviani S, Moltò A, Ea H-K, Neveu S, Gill G, Brunier L, et al. Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Res Ther. 2013;15:R123.

    Article  PubMed  Google Scholar 

  11. propertieshttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

  12. Kapur S, Bonk ME. Rilonacept (Arcalyst), an Interleukin-1 Trap for the Treatment of Cryopyrin-Associated Periodic Syndromes. P T. 2009;34(3):138–41.

    PubMed Central  PubMed  Google Scholar 

  13. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HSB, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther. 2013;15(1):R25.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in the treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis. 2009;68:1613–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Mitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology. 2013;52(7):1285–92.

    Article  CAS  PubMed  Google Scholar 

  16. •• Schumacher HR, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, et al. Rilonacept (IL-1 Trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase 2 clinical trial. Arthritis Rheum. 2012;64(3):876–84. An important study demonstrating the use of IL-1 blockade in gout prophylaxis.

  17. So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for treatment of acute flares in refractory gouty arthritis. Arthritis Rheum. 2010;62(10):3064–74. PA.

    Article  CAS  PubMed  Google Scholar 

  18. Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13:R53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. •• Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol therapy: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71. An important study demonstrating the use of IL-1 blockade in gout prophylaxis.

  20. Schlesinger N, Alten R, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their extensions. Ann Rheum Dis. 2012;71:1839–48.

    Article  CAS  PubMed  Google Scholar 

  21. de La Mata Llord J, Gonzalez Crespo R, Maese Manzano J. Treatment of rheumatoid arthritis with anakinra: a systematic review. Reumatol Clin. 2007;3(4):153–8.

    Article  Google Scholar 

  22. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Naomi Schlesinger has received grant support from Novartis; has served on advisory boards for Novartis, Takeda, Savient, Enzyme Rx, URL Pharma, and Sobi; has served as a consultant for Novartis and Sobi; and has served on speakers bureaus for Novartis, Takeda, and Savient.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Rutgers- Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Naomi Schlesinger

Authors
  1. Naomi Schlesinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naomi Schlesinger.

Additional information

This article is part of the Topical Collection on Crystal Arthritis

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlesinger, N. Anti-Interleukin-1 Therapy in the Management of Gout. Curr Rheumatol Rep 16, 398 (2014). https://doi.org/10.1007/s11926-013-0398-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0398-z

Keywords

Search

Navigation